74SOFTWARE 38.300 € (+1,86 %) ALTAREA 96.400 € (-0,52 %) LAURENT-PERRIER 88.400 € (0,00 %) 
BE SEMICONDUCTOR 314.300 € (-0,85 %) ATOS 36.240 € (+4,50 %) SAINT GOBAIN 78.080 € (+3,06 %) NEDAP 96.900 € (-0,92 %) ASM INTERNATIONAL 1 025.000 € (+0,99 %) SAFRAN 316.400 € (+3,36 %) PHILIPS KON 23.080 € (+1,18 %) AHOLD DEL 36.010 € (-0,99 %) AKZO NOBEL 58.900 € (+1,94 %) PROSUS 39.570 € (+0,70 %) 
INPOST 15.290 € (-0,20 %) ING GROEP N.V. 26.325 € (+1,41 %) CVC CAPITAL 13.260 € (+2,39 %) IMCD 88.820 € (+0,23 %) PUBLICIS GROUPE SA 89.820 € (+0,18 %) EUROFINS SCIENT. 63.380 € (-1,09 %) BNP PARIBAS ACT.A 98.650 € (+2,03 %) COVIVIO 55.200 € (+0,27 %) NN GROUP 73.660 € (+0,52 %) AALBERTS NV 40.440 € (+0,85 %) AXA 41.880 € (+2,50 %) SOCIETE GENERALE 76.000 € (+3,54 %) DBV TECHNOLOGIES 3.188 € (+5,77 %) CROSSJECT 1.926 € (-0,31 %) WOLTERS KLUWER 60.240 € (-1,41 %) ADYEN 858.900 € (+3,68 %) ABN AMRO BANK N.V. 35.280 € (+1,76 %) WENDEL 85.450 € (+1,67 %) CREDIT AGRICOLE 16.930 € (+1,23 %) SPIE 49.900 € (+1,96 %) EURONEXT 148.300 € (+0,07 %) ASML HOLDING 1 622.200 € (-0,45 %) 
UNILEVER 50.580 € (-0,43 %) ARCELORMITTAL SA 59.920 € (-1,12 %) UMG 17.945 € (+1,04 %) CEGEDIM 11.320 € (+0,53 %) STMICROELECTRONICS 68.450 € (+1,03 %) BOUYGUES 50.680 € (+0,76 %) CSG 13.910 € (-3,99 %) NICOX 0.370 € (+6,78 %) ENGIE 27.300 € (-0,76 %) SHELL PLC 35.680 € (-4,37 %) STELLANTIS NV 6.091 € (+3,24 %) BUREAU VERITAS 26.120 € (+2,59 %) QWAMPLIFY 1.800 € (-9,55 %) SAFE 0.570 € (-8,06 %) FREELANCE.COM 2.810 € (+0,36 %) BURELLE 411.000 € (+1,48 %) TOTALENERGIES 73.000 € (-4,43 %) DERICHEBOURG 10.200 € (-0,49 %) ACCOR 48.780 € (+2,93 %) VALEO 14.855 € (+2,24 %) BRUNEL INTERNAT 7.160 € (-0,83 %) 2CRSI 50.150 € (+0,46 %) MERSEN 44.600 € (+1,69 %) L'OREAL 385.850 € (-1,13 %) VERALLIA 19.570 € (-2,83 %) |
15/06/2026 22:59
BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARESPress release BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARESParis (France) and Cambridge (Massachusetts, U.S.), June 15, 2026, at 11:00 p.m CET. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces the temporary suspension of the trading of its shares by Euronext. This suspension results from the non-publication of the annual financial report for the fiscal year ended December 31, 2025, due to an operational delay in the preparation of the financial statements. The report will be published following certification of the accounts by the statutory auditors, which is expected no later than the end of July 2026. Trading of Biophytis shares on Euronext Growth Paris was suspended on June 15, 2026, and is expected to resume following the publication of the annual financial report. The Company will keep the market informed of the date on which trading will resume. * * * About BiophytisBiophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. Biophytis ContactInvestor relations Media relations Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière